CDK4/6 Inhibition Active in Recurrent Low-Grade Serous Ovarian Cancer

(MedPage Today) -- TAMPA, Fla. -- About a fourth of patients with recurrent low-grade serous ovarian cancer (LGSOC) obtained durable responses to the combination of CDK4/6 inhibitor ribociclib (Kisqali) and letrozole, a small single-arm trial...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news